Edition:
United States

Benitec Biopharma Ltd (BLT.AX)

BLT.AX on Australia Stock Exchange

0.16AUD
24 Mar 2017
Change (% chg)

$0.00 (+3.23%)
Prev Close
$0.16
Open
$0.16
Day's High
$0.17
Day's Low
$0.16
Volume
78,683
Avg. Vol
500,876
52-wk High
$0.21
52-wk Low
$0.09

Latest Key Developments (Source: Significant Developments)

Benitec biopharma signs new research and collaboration agreement
Wednesday, 21 Dec 2016 05:42pm EST 

Benitec Biopharma Ltd :New research and collaboration agreement has been signed with royal holloway university of london.  Full Article

Benitec Biopharma says Greg West appointed CEO
Wednesday, 10 Aug 2016 05:00am EDT 

Benitec Biopharma Ltd : Says Bryan Dulhunty appointed CFO .Cliff Holloway appointed CBO and COO.  Full Article

Benitec Biopharma appoints Greg West as chief executive officer
Tuesday, 9 Aug 2016 07:32pm EDT 

Benitec Biopharma Ltd : Restructuring of senior executive team . Says appointment of Greg West as chief executive officer .Bryan Dulhunty appointed as CFO.  Full Article

Benitec Biopharma receives cash refund under government's R&D tax incentive scheme
Thursday, 16 Jun 2016 12:36am EDT 

Benitec Biopharma Ltd : It has received a $3.6 million cash refund under the federal government's research and development tax incentive scheme .  Full Article

Benitec Biopharma Ltd says Greg West appointed interim CEO
Tuesday, 8 Dec 2015 04:59pm EST 

Benitec Biopharma Ltd:Benitec CFO appointed interim CEO.Says CEO and managing director Peter French Resigned.Says Greg West appointed interim CEO.  Full Article

Benitec Biopharma Ltd announces closing of initial public offering in United States with listing on NASDAQ
Monday, 24 Aug 2015 07:30am EDT 

Benitec Biopharma Ltd:Says closing of its U.S. initial public offering of 1,500,000 American Depositary Shares, representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares.Says each ADS represents 20 ordinary shares of Benitec.Says gross proceeds from offering were $13.8 million, before deducting underwriting discounts and commissions and other offering expenses.Says net proceeds from the offering will be used primarily to advance Benitec's therapeutic programs.Says ADSs and warrants trade on The NASDAQ Capital Market under the symbols BNTC and BNTCW, respectively.Says Maxim Group LLC acted as sole book-running manager for offering.  Full Article

Benitec Biopharma announces pricing of IPO on Nasdaq
Tuesday, 18 Aug 2015 08:30am EDT 

Benitec Biopharma Ltd:Announces pricing of an initial public offering in the United States with listing on NASDAQ.Pricing of U.S. initial public offering of 1.5 million ads at a price of US$9.21 per ads.  Full Article

Benitec Biopharma acquires full rights to Hepatitis B program
Thursday, 9 Jul 2015 07:15am EDT 

Benitec Biopharma Ltd:Acquires the full rights to the pre-clinical ddRNAi-based Hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies.  Full Article

Benitec acquires full rights to Hepatitis B program
Wednesday, 8 Jul 2015 07:29pm EDT 

Benitec Biopharma Ltd:Announces that Benitec has acquired the full rights to the pre--‐ clinical ddRNAi--‐based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies.  Full Article

Benitec Biopharma Ltd announces plans for an initial public offering in United States with listing on NASDAQ
Monday, 22 Jun 2015 07:41pm EDT 

Benitec Biopharma Ltd:Says that on June 22, it filed a registration statement on Form F-1 with U.S. Securities and Exchange Commission in connection with initial public offering (IPO) in the United States with listing on NASDAQ Global Select Market (NASDAQ).Says Benitec proposes to raise about $60-$70 million under IPO through issuance of up to 5,750,000 American Depositary Shares (ADSs), representing 115,000,000 fully paid ordinary shares of Benitec.Proposes to undertake IPO and list the ADSs on NASDAQ in order to access US public equity market.  Full Article

More From Around the Web

BRIEF-Benitec Biopharma initiates work on two oncology pipeline programs

* Initiated work on two new oncology pipeline programs after executing a research collaboration agreement with Nant Capital Llc Source text for Eikon: Further company coverage: